LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
SER
Serina Therapeutics, Inc.
There isn't enough reported data to score SER yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
SER Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
SER's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
SER PE Valuation
SER has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
SER Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| -- | |
| -- | |
| Limited | |
| Moderate |
Analysts expect SER's losses to shrink, with revenue holding steady.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over SER on earnings quality, reporting a profit while its opponent remains loss making.
SER Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.75 | +$0.10 |
| Q2 2026 | -$1.89 | -$0.62 |
| Q1 2026 | -$2.00 | -$1.90 |
| Q4 2025 | -$1.91 | +$1.08 |
| Q3 2023 | -$13.13 | -$4.20 |
| Q2 2023 | -$10.27 | -$1.70 |
| Q1 2023 | -$10.27 | -$1.70 |
| Q4 2022 | -$9.69 | -$1.48 |
SER is still losing money, but far less than before: $1.75 per share over the past year, against $13.13 at its worst in late 2023.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the stronger quarterly revenue trend. Revenue is up 39% for LLY versus down 3.8% for SER.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over SER on profitability, with a higher operating margin.
SER Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2025 | $130K | +155% |
| Q3 2024 | $14K | -79% |
| Q2 2024 | $51K | +467% |
| Q1 2024 | $5K | -50% |
| Q4 2023 | $56K | +600% |
| Q3 2023 | $67K | +644% |
| Q2 2023 | $9K | -25% |
| Q1 2023 | $10K | +100% |
SER's revenue fell from its 2019 peak and has held roughly level since: $125,000 last quarter, down 3.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -6289% | N/A |
| Q2 2025 | -4281% | +3300 points |
| Q3 2024 | -37943% | -34426 points |
| Q2 2024 | -7580% | +13375 points |
| Q1 2024 | -46420% | -24840 points |
| Q4 2023 | -6227% | +16048 points |
| Q3 2023 | -3516% | +13706 points |
| Q2 2023 | -20956% | -7697 points |
SER's operating margin was −6289% last quarter, up 40131 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over SER on cash generation, producing positive trailing cash flow while its opponent burns cash.
SER Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$5.5M | -$1.6M |
| Q2 2026 | -$6.7M | -$2.9M |
| Q1 2026 | -$4.6M | -$271K |
| Q4 2025 | -$6M | -$1.4M |
| Q3 2025 | -$3.9M | -$898K |
| Q2 2025 | -$3.8M | +$4.2M |
| Q1 2025 | -$4.3M | -$2.7M |
| Q4 2024 | -$4.6M | -$2.5M |
SER has burned cash in almost every quarter: −$23M over the past year, against −$17M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over SER on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
SER Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +55% | +9M shares |
| 1 year | +146% | +15.1M shares |
| 3 years | +2292% | +24.4M shares |
SER has 25M diluted shares, up 146% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
SER Net Leverage
SER's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
SER Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.3 | Neutral |
| Stochastic | 23.0 | Neutral |
SER's weekly RSI is 38 (neutral) and its Stochastic is 23 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
SER PE vs Healthcare Sector
SER has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over SER on trend strength, trading above more of its moving averages.
SER Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.77 | 20% below |
| 20 week MA | $2.11 | 33% below |
| 50 week MA | $2.16 | 35% below |
| 100 week MA | $3.68 | 62% below |
| 200 week MA | $9.95 | 86% below |
SER is in a downtrend: it's below all five of its weekly moving averages, and 86% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over SER on returns for 2026, with the stronger performance.
SER Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $62.1 | $59.3 | -4.6% |
| 2021 | $59.3 | $21.4 | -64% |
| 2022 | $21.4 | $19.6 | -8.4% |
| 2023 | $19.6 | $13.8 | -30% |
| 2024 | $13.8 | $5.64 | -59% |
| 2025 | $5.64 | $2.66 | -53% |
| 2026 YTD | $2.66 | $1.41 | -47% |
SER has finished every year since 2020 lower, and it's down 47% so far in 2026.